# BridgeBio Pharma, Inc.: filings

BBIO · Nasdaq · CIK 1743881 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bbio.md) · [Financials](/companies/bbio/financials.md) · [Filings](/companies/bbio/filings.md) · [Insiders](/companies/bbio/insiders.md)

## Reports and events: 183 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 408, 8-K 107, 144 87, 3 29, 10-Q 23, SC 13D/A 18, S-8 13, SC 13G/A 13, SCHEDULE 13D/A 11, CORRESP 8, DEF 14A 8, 10-K 7, DEFA14A 7, S-3ASR 7, 425 6, SCHEDULE 13G/A 6, UPLOAD 6, 4/A 5, 424B5 4, ARS 4, S-1/A 4, SC 13D 4, SC 13G 4, SEC STAFF LETTER 4, 424B7 3, 5 3, SCHEDULE 13G 3, DRS/A 2, DRSLTR 2, EFFECT 2, PRE 14A 2, 424B3 1, 424B4 1, 5/A 1, 8-A12B 1, CERT 1, CT ORDER 1, DEFM14A 1, DRS 1, S-1 1, S-1MEF 1, S-4 1, S-4/A 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:52 ET | [10-Q](/filings/0001743881-26-000034.md) | Quarterly report, period 2026-09-30 | 0001743881-26-000034 |
| 2026-10-29 | 16:03 ET | [8-K](/filings/0001743881-26-000033.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001743881-26-000033 |
| 2026-10-13 | 06:01 ET | [8-K](/filings/0001140361-26-039334.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-039334 |
| 2026-08-31 | 15:54 ET | [8-K](/filings/0001140361-26-035055.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-035055 |
| 2026-08-17 | 17:30 ET | [SCHEDULE 13D/A](/filings/0001140361-26-033404.md) | Ownership report, active investor, amended | 0001140361-26-033404 |
| 2026-08-17 | 09:05 ET | [8-K](/filings/0001140361-26-033282.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-033282 |
| 2026-08-10 | 16:31 ET | [10-Q](/filings/0001743881-26-000027.md) | Quarterly report, period 2026-06-30 | 0001743881-26-000027 |
| 2026-08-10 | 16:03 ET | [8-K](/filings/0001743881-26-000026.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001743881-26-000026 |
| 2026-07-22 | 16:34 ET | [8-K](/filings/0001140361-26-029291.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-029291 |
| 2026-07-10 | 19:03 ET | [SCHEDULE 13D/A](/filings/0000905148-26-003237.md) | Ownership report, active investor, amended | 0000905148-26-003237 |
| 2026-07-02 | 16:23 ET | [8-K](/filings/0001140361-26-027445.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-027445 |
| 2026-06-26 | 08:30 ET | [8-K](/filings/0001140361-26-026506.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001140361-26-026506 |
| 2026-05-27 | 16:01 ET | [8-K](/filings/0001140361-26-022979.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-022979 |
| 2026-05-13 | 16:01 ET | [8-K](/filings/0001140361-26-021036.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-021036 |
| 2026-05-08 | 09:01 ET | [8-K](/filings/0001140361-26-019761.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001140361-26-019761 |
| 2026-05-07 | 16:31 ET | [10-Q](/filings/0001743881-26-000019.md) | Quarterly report, period 2026-03-31 | 0001743881-26-000019 |
| 2026-05-07 | 16:02 ET | [8-K](/filings/0001743881-26-000018.md) | 2.02 Results of operations; 8.01 Other events | 0001743881-26-000018 |
| 2026-04-24 | 16:25 ET | [DEF 14A](/filings/0001140361-26-016723.md) | Proxy statement, period 2026-06-22 | 0001140361-26-016723 |
| 2026-04-02 | 18:40 ET | [SCHEDULE 13D/A](/filings/0000905148-26-001499.md) | Ownership report, active investor, amended | 0000905148-26-001499 |
| 2026-03-30 | 17:30 ET | [8-K](/filings/0001140361-26-011991.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-011991 |
| 2026-02-24 | 16:51 ET | [10-K](/filings/0001743881-26-000009.md) | Annual report, period 2025-12-31 | 0001743881-26-000009 |
| 2026-02-24 | 16:04 ET | [8-K](/filings/0001743881-26-000008.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001743881-26-000008 |
| 2026-02-17 | 20:46 ET | [SCHEDULE 13D/A](/filings/0000905148-26-000914.md) | Ownership report, active investor, amended | 0000905148-26-000914 |
| 2026-02-12 | 16:05 ET | [8-K](/filings/0001140361-26-004995.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-004995 |
| 2026-01-21 | 16:07 ET | [8-K](/filings/0001140361-26-001843.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-001843 |
| 2026-01-12 | 16:06 ET | [8-K](/filings/0001140361-26-000971.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-000971 |
| 2025-11-14 | 16:52 ET | [SCHEDULE 13D/A](/filings/0000905148-25-004059.md) | Ownership report, active investor, amended | 0000905148-25-004059 |
| 2025-10-29 | 16:57 ET | [10-Q](/filings/0001743881-25-000012.md) | Quarterly report, period 2025-09-30 | 0001743881-25-000012 |
| 2025-10-29 | 16:09 ET | [8-K](/filings/0001140361-25-039705.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-039705 |
| 2025-10-29 | 16:02 ET | [8-K](/filings/0001743881-25-000010.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001743881-25-000010 |
| 2025-10-27 | 16:11 ET | [8-K](/filings/0001140361-25-039463.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-039463 |
| 2025-08-14 | 20:32 ET | [SCHEDULE 13D/A](/filings/0000905148-25-003013.md) | Ownership report, active investor, amended | 0000905148-25-003013 |
| 2025-08-05 | 16:57 ET | [10-Q](/filings/0000950170-25-103192.md) | Quarterly report, period 2025-06-30 | 0000950170-25-103192 |
| 2025-08-05 | 16:04 ET | [8-K](/filings/0000950170-25-102985.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-102985 |
| 2025-07-01 | 19:49 ET | [SCHEDULE 13D/A](/filings/0000905148-25-002298.md) | Ownership report, active investor, amended | 0000905148-25-002298 |
| 2025-07-02 | 17:42 ET | [8-K](/filings/0001140361-25-024413.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001140361-25-024413 |
| 2025-06-23 | 16:29 ET | [8-K](/filings/0001140361-25-023362.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001140361-25-023362 |
| 2025-05-14 | 17:52 ET | [SCHEDULE 13D/A](/filings/0001140361-25-019024.md) | Ownership report, active investor, amended | 0001140361-25-019024 |
| 2025-04-30 | 06:01 ET | [DEF 14A](/filings/0001140361-25-016452.md) | Proxy statement, period 2025-06-20 | 0001140361-25-016452 |
| 2025-04-29 | 17:05 ET | [10-Q](/filings/0000950170-25-060314.md) | Quarterly report, period 2025-03-31 | 0000950170-25-060314 |
| 2025-04-29 | 16:04 ET | [8-K](/filings/0000950170-25-060085.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-060085 |
| 2025-03-17 | 16:32 ET | [8-K](/filings/0001140361-25-009063.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-25-009063 |
| 2025-03-12 | 16:28 ET | [SCHEDULE 13D/A](/filings/0000905148-25-000909.md) | Ownership report, active investor, amended | 0000905148-25-000909 |
| 2025-03-07 | 18:15 ET | [SCHEDULE 13D/A](/filings/0001140361-25-007701.md) | Ownership report, active investor, amended | 0001140361-25-007701 |
| 2025-02-28 | 16:11 ET | [8-K](/filings/0001140361-25-006524.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-006524 |
| 2025-02-20 | 16:00 ET | [10-K](/filings/0000950170-25-024119.md) | Annual report, period 2024-12-31 | 0000950170-25-024119 |
| 2025-02-20 | 07:31 ET | [8-K](/filings/0000950170-25-023741.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-023741 |
| 2025-01-31 | 19:18 ET | [SCHEDULE 13D/A](/filings/0000905148-25-000308.md) | Ownership report, active investor, amended | 0000905148-25-000308 |
| 2025-01-13 | 16:53 ET | [8-K](/filings/0001140361-25-000943.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-000943 |
| 2024-11-25 | 21:16 ET | [8-K](/filings/0001140361-24-047704.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-24-047704 |

Page 1 of 4. [Older](/companies/bbio/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 29, 2026, 19:20 ET. No prices; not investment advice.